Jason Rhodes Sells 480,240 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 480,240 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the completion of the sale, the director directly owned 875,912 shares in the company, valued at approximately $19,962,034.48. The trade was a 35.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Performance

NASDAQ:DYN remained flat at $23.83 during mid-day trading on Wednesday. 2,528,261 shares of the company traded hands, compared to its average volume of 2,034,586. The firm has a market cap of $3.94 billion, a P/E ratio of -7.40 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $25.00. The company has a fifty day simple moving average of $18.89 and a two-hundred day simple moving average of $18.24.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the company earned ($1.05) EPS. On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

DYN has been the topic of a number of analyst reports. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. Finally, TD Cowen started coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $34.17.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DYN. Hilton Head Capital Partners LLC acquired a new position in Dyne Therapeutics in the first quarter valued at about $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth about $84,000. Steward Partners Investment Advisory LLC increased its stake in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.